Excision BioTherapeutics

Excision BioTherapeutics is pioneering the application of CRISPR gene-editing technology to directly target and eliminate latent viral DNA from the human genome, focusing on large and complex viruses like HIV, HSV, and HBV. The company's lead program, EBT-101, is a first-in-human CRISPR-based therapy for HIV that has completed a Phase 1/2 trial, demonstrating initial safety and proof-of-concept. As a private, pre-revenue entity, Excision is advancing a pipeline of in vivo gene therapies with the potential to address significant unmet medical needs in virology and genetic diseases. Its strategy combines a novel therapeutic approach with a platform capable of targeting multiple indications.

Proprietary CRISPR-Cas gene-editing platform using AAV delivery and multiplexed guide RNAs to excise latent viral DNA from the human genome.

Excision competes with other biotechs pursuing an HIV cure via different mechanisms (e.g., 'shock and kill', broadly neutralizing antibodies) and with large gene-editing platforms (e.g., CRISPR Therapeutics, Intellia Therapeutics) that have greater resources but are primarily focused on genetic diseases. Its unique focus on viral DNA excision provides a distinct competitive niche.